You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethylprednisolone
Accession NumberDB00959  (APRD00342)
TypeSmall Molecule
GroupsApproved
Description

A prednisolone derivative with similar anti-inflammatory action. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dioneNot AvailableNot Available
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dioneNot AvailableNot Available
1-dehydro-6alpha-MethylhydrocortisoneNot AvailableNot Available
1-dehydro-6α-methylhydrocortisoneNot AvailableNot Available
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dioneNot AvailableNot Available
delta(1)-6alpha-MethylhydrocortisoneNot AvailableNot Available
MedrateNot AvailableNot Available
MedrolNot AvailableNot Available
MedroneNot AvailableNot Available
MethylprednisolonNot AvailableNot Available
MethylprednisoloneNot AvailableNot Available
MethylprednisolonumLatinINN
MetilprednisolonaSpanishINN
SolometNot AvailableNot Available
UrbasonNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Solu-medrolinjection, powder, for solution500 mg/mLintramuscular; intravenousPharmacia and Upjohn Company1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution1 g/mLintramuscular; intravenousPharmacia and Upjohn Company1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet2 mgoralPharmacia and Upjohn Company2013-09-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet8 mgoralPharmacia and Upjohn Company1957-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousPharmacia and Upjohn Company1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousPharmacia and Upjohn Company1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousPharmacia and Upjohn Company1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousPharmacia and Upjohn Company1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet2 mgoralPharmacia and Upjohn Company1957-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet4 mgoralPharmacia and Upjohn Company1957-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet16 mgoralPharmacia and Upjohn Company1957-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet32 mgoralPharmacia and Upjohn Company1957-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension20 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia and Upjohn Company1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia and Upjohn Company1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia and Upjohn Company1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia and Upjohn Company1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia and Upjohn Company1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution1 g/mLintramuscular; intravenousPharmacia and Upjohn Company1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution500 mg/mLintramuscular; intravenousPharmacia and Upjohn Company1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolkitPharmacia and Upjohn Company1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissuePharmacia and Upjohn Company1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia and Upjohn Company1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissuePharmacia and Upjohn Company1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia and Upjohn Company1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet4 mgoralStat Rx USA1957-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissueRebel Distributors Corp1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet32 mgoralREMEDYREPACK INC.2011-10-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension40 mg/mLintramuscularREMEDYREPACK INC.2013-06-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolpowder, for solution125 mg/mLintravenousREMEDYREPACK INC.2011-12-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension40 mgintramuscularREMEDYREPACK INC.2013-04-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet4 mgoralREMEDYREPACK INC.2013-02-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralLake Erie Medical DBA Quality Care Products LLC2012-02-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet4 mgoralA S Medication Solutions Llc1957-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution1 gintravenousREMEDYREPACK INC.2013-02-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution40 mgintravenousREMEDYREPACK INC.2013-04-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-04-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-04-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroltablet4 mgoralA S Medication Solutions Llc1957-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousA S Medication Solutions Llc1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissueDispensing Solutions, Inc.1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissueCardinal Health1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissueCardinal Health1959-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet8 mgoralGreenstone LLC2013-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet16 mgoralGreenstone LLC2013-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet32 mgoralGreenstone LLC2013-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralGreenstone LLC2011-10-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousUs Med Source, Llc2014-07-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-medrolinjection, suspension80 mg/mLintramuscularREMEDYREPACK INC.2014-09-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralAltura Pharmaceuticals, Inc.2010-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralKeltman Pharmaceuticals Inc.2007-09-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methylprednisolonetablet16 mgoralKAISER FOUNDATION HOSPITALS2012-09-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
A-methapredinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousHospira, Inc.2005-12-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
A-methapredinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousHospira, Inc.2005-12-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralQualitest Pharmaceuticals1998-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralSandoz Inc1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralSTAT Rx USA LLC1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralRebel Distributors Corp.1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralAidarex Pharmaceuticals LLC1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralLake Erie Medical DBA Quality Care Products LLC1998-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralSTAT Rx USA LLC1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralREMEDYREPACK INC.2012-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralREMEDYREPACK INC.2012-03-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralREMEDYREPACK INC.2012-07-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralUnit Dose Services1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralBreckenridge Pharmaceutical, Inc.2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralA S Medication Solutions Llc1998-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralPhysicians Total Care, Inc.2009-10-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralPhysicians Total Care, Inc.1994-11-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralDispensing Solutions, Inc.1998-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralClinical Solutions Wholesale1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet8 mgoralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet16 mgoralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet32 mgoralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralDIRECT RX2014-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralbryant ranch prepack1997-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralBlue Point Laboratories2013-08-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralAmerican Health Packaging2013-11-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralPreferred Pharmaceuticals, Inc.2013-09-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methylprednisolonetablet4 mgoralPreferred Pharmaceuticals, Inc.2014-10-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
MedrateNot Available
MedroneNot Available
MeproloneNot Available
SolometNot Available
UrbasonNot Available
Brand mixtures
Brand NameIngredients
Depo-Medrol with LidocaineLidocaine Hydrochloride + Methylprednisolone Acetate
Medrol Acne LotionAluminum Chlorohydrate + Methylprednisolone Acetate + Sulfur
Methylprednisolone Sodium Succinate for InjectionMethylprednisolone + Water
Neo-MedrolMethylprednisolone Acetate + Neomycin Sulfate
Neo-Medrol Acne LotionAluminum Chlorohydrate + Methylprednisolone Acetate + Neomycin Sulfate + Sulfur
SaltsNot Available
Categories
CAS number83-43-2
WeightAverage: 374.4706
Monoisotopic: 374.20932407
Chemical FormulaC22H30O5
InChI KeyVHRSUDSXCMQTMA-PJHHCJLFSA-N
InChI
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
IUPAC Name
(1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationAdjunctive therapy for short-term administration in rheumatoid arthritis.
PharmacodynamicsMethylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents.
Mechanism of actionUnbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
AbsorptionOral bioavailability 80-99%
Volume of distributionNot Available
Protein binding78%
Metabolism

Hepatic

Route of eliminationNot Available
Half life1-3 hours
ClearanceNot Available
ToxicityLD50=2000 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9911
Blood Brain Barrier+0.9484
Caco-2 permeable-0.6404
P-glycoprotein substrateSubstrate0.7812
P-glycoprotein inhibitor INon-inhibitor0.7489
P-glycoprotein inhibitor IINon-inhibitor0.604
Renal organic cation transporterNon-inhibitor0.769
CYP450 2C9 substrateNon-substrate0.8415
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7582
CYP450 1A2 substrateNon-inhibitor0.9473
CYP450 2C9 substrateNon-inhibitor0.907
CYP450 2D6 substrateNon-inhibitor0.9513
CYP450 2C19 substrateNon-inhibitor0.9026
CYP450 3A4 substrateNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9167
Ames testNon AMES toxic0.9337
CarcinogenicityNon-carcinogens0.9529
BiodegradationNot ready biodegradable0.9492
Rat acute toxicity2.0025 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9459
hERG inhibition (predictor II)Non-inhibitor0.5985
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Cadista pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Heather drug co inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Abbott laboratories hosp products div
  • Hemopharm usa corp
  • Hospira inc
  • Elkins sinn div ah robins co inc
  • Organon usa inc
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Bedford laboratories
  • International medication systems ltd
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionintramuscular; intravenous1 g/mL
Injection, powder, for solutionintramuscular; intravenous125 mg/mL
Injection, powder, for solutionintramuscular; intravenous40 mg/mL
Injection, powder, for solutionintramuscular; intravenous500 mg/mL
Injection, powder, for solutionintravenous1 g
Injection, powder, for solutionintravenous40 mg
Injection, powder, lyophilized, for solutionintramuscular; intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionintramuscular; intravenous40 mg/mL
Injection, suspensionintra-articular; intralesional; intramuscular; soft tissue40 mg/mL
Injection, suspensionintra-articular; intralesional; intramuscular; soft tissue80 mg/mL
Injection, suspensionintralesional; intramuscular; intrasynovial; soft tissue20 mg/mL
Injection, suspensionintralesional; intramuscular; intrasynovial; soft tissue40 mg/mL
Injection, suspensionintralesional; intramuscular; intrasynovial; soft tissue80 mg/mL
Injection, suspensionintramuscular40 mg
Injection, suspensionintramuscular40 mg/mL
Injection, suspensionintramuscular80 mg/mL
Kit
Powder, for solutionintravenous125 mg/mL
Tabletoral16 mg
Tabletoral2 mg
Tabletoral32 mg
Tabletoral4 mg
Tabletoral8 mg
Prices
Unit descriptionCostUnit
Methylprednisolone powder96.25USD g
Methylprednisolone ac powdr40.09USD g
Methylprednisolone ss 1 gm vial31.2USD vial
Solu-medrol 1 gm vial24.43USD vial
Solu-medrol (pf) 500 mg vial20.9USD vial
MethylPREDNISolone (Pak) 21 4 mg tablet Disp Pack16.99USD disp
Methylprednisolone 500 mg vial15.6USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Methylprednisolone 125 mg vial10.0USD vial
Methylprednisolone 80 mg/ml vial9.12USD ml
Depo-medrol 40 mg/ml vial6.41USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Methylprednisolone 40 mg/ml vial5.22USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone 32 mg tablet4.62USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone 16 mg tablet3.17USD tablet
Methylprednisolone 40 mg vial3.0USD vial
A-methapred 40 mg vial2.36USD vial
Medrol 16 mg tablet2.28USD tablet
Medrol 8 mg tablet2.23USD tablet
Methylprednisolone 8 mg tablet1.74USD tablet
Methylprednisolone 4 mg tablet1.68USD tablet
Medrol 4 mg dosepak1.59USD each
Medrol 4 mg tablet0.99USD tablet
Medrol 2 mg tablet0.84USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point232.5 °CPhysProp
water solubility120 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.5Not Available
logS-2.99ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.109 mg/mLALOGPS
logP2.06ALOGPS
logP1.56ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity103.04 m3·mol-1ChemAxon
Polarizability40.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Klaus Annen, Karl Petzoldt, Henry Laurent, Rudolf Wiechert, Helmut Hofmeister, “Novel 6.alpha.-methylprednisolone derivatives, their preparation, and their use.” U.S. Patent US4587236, issued March, 1973.

US4587236
General Reference
  1. Sloka JS, Stefanelli M: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005 Aug;11(4):425-32. Pubmed
External Links
ATC CodesD07AA01D10AA02H02AB04
AHFS Codes
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (244 KB)
MSDSDownload (72.6 KB)
Interactions
Drug Interactions
Drug
AcetohexamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Acetylsalicylic acidMay enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.
AldesleukinCorticosteroids may diminish the antineoplastic effect of Aldesleukin.
AlogliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Aluminum hydroxideMay decrease the bioavailability of Corticosteroids (Oral).
AminoglutethimideMay increase the metabolism of Corticosteroids (Systemic).
Amphotericin BCorticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.
AprepitantMay increase the serum concentration of Corticosteroids (Systemic).
AripiprazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
AtazanavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
BoceprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
CalcitriolCorticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.
Calcium carbonateMay decrease the bioavailability of Corticosteroids (Oral).
CanagliflozinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
CarbamazepineCYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.
ChlorpropamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
ClarithromycinCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
ColesevelamMay decrease the absorption of Corticosteroids (Oral).
ConivaptanCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
DarunavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
DeferasiroxCorticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.
DelavirdineCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
DenosumabMay enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.
DihydrotestosteroneCorticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens.
DofetilideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.
EnzalutamideCYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.
FosamprenavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
FosaprepitantMay increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.
FosphenytoinCYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.
GliclazideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GlimepirideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GliquidoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GlyburideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
HyaluronidaseCorticosteroids may diminish the therapeutic effect of Hyaluronidase.
HydrocodoneCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
IndacaterolMay enhance the hypokalemic effect of Corticosteroids (Systemic).
IndinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
Insulin AspartHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin DetemirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlargineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlulisineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin LisproHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin RegularHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin, isophaneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
IsoniazidCorticosteroids (Systemic) may decrease the serum concentration of Isoniazid.
ItraconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
LeflunomideImmunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.
LinagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
LomitapideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.
LopinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
Magnesium oxideMay decrease the bioavailability of Corticosteroids (Oral).
MetforminHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
MifepristoneMay diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic).
MitotaneMay decrease the serum concentration of Corticosteroids (Systemic).
NatalizumabImmunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.
NefazodoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
NelfinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
OxandroloneCorticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens.
PhenobarbitalCYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.
PhenytoinCYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.
PimecrolimusMay enhance the adverse/toxic effect of Immunosuppressants.
PimozideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.
PosaconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
PrimidoneCYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.
RepaglinideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
RifampicinCYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.
RifapentineCYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.
RitonavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
RoflumilastMay enhance the immunosuppressive effect of Immunosuppressants.
Salicylate-sodiumMay enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.
SaquinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
SaxagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Sipuleucel-TImmunosuppressants may diminish the therapeutic effect of Sipuleucel-T.
TelaprevirMay increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir.
TelithromycinCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
TestosteroneCorticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens.
TofacitinibImmunosuppressants may enhance the immunosuppressive effect of Tofacitinib.
TolbutamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
TrastuzumabMay enhance the neutropenic effect of Immunosuppressants.
VildagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
VoriconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
WarfarinCorticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.
Food InteractionsNot Available

Targets

1. Glucocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Glucocorticoid receptor P04150 Details

References:

  1. Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70. Epub 2006 Dec 19. Pubmed
  2. Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM: Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl). 2006 Dec;189(2):225-35. Epub 2006 Oct 3. Pubmed
  3. Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY: Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G590-8. Epub 2006 Oct 26. Pubmed
  4. Quesnell RR, Han X, Schultz BD: Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium. Am J Physiol Cell Physiol. 2007 May;292(5):C1739-45. Epub 2007 Jan 24. Pubmed
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Oka A, Oda M, Saitoh H, Nakayama A, Takada M, Aungst BJ: Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6. Pubmed
  2. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. Pubmed
  3. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 11, 2014 08:39